Josh Wolfe of Lux Capital shared his vision of how public and private capital will fund NBIC-oriented companies. Not shy to admit that his fund is just getting interested in companies that go beyond "ordinary" nano-material science, Josh gave a clear "thumbs up" to the long-term viability of the nano-biotechnology market.